MSFT   187.46 (+2.48%)
FB   230.86 (+2.02%)
GOOGL   1,442.15 (+1.97%)
AMZN   2,487.30 (+1.09%)
NVDA   358.50 (+2.24%)
CGC   16.53 (-0.60%)
BABA   219.69 (+0.76%)
MU   54.01 (+5.45%)
GE   7.91 (+2.20%)
TSLA   885.50 (+2.44%)
T   32.82 (+3.21%)
ACB   13.90 (-2.32%)
F   7.32 (+11.42%)
GILD   76.90 (-0.83%)
DIS   124.79 (+0.89%)
NFLX   420.04 (+1.38%)
BAC   28.18 (+5.23%)
BA   204.81 (+11.13%)
MSFT   187.46 (+2.48%)
FB   230.86 (+2.02%)
GOOGL   1,442.15 (+1.97%)
AMZN   2,487.30 (+1.09%)
NVDA   358.50 (+2.24%)
CGC   16.53 (-0.60%)
BABA   219.69 (+0.76%)
MU   54.01 (+5.45%)
GE   7.91 (+2.20%)
TSLA   885.50 (+2.44%)
T   32.82 (+3.21%)
ACB   13.90 (-2.32%)
F   7.32 (+11.42%)
GILD   76.90 (-0.83%)
DIS   124.79 (+0.89%)
NFLX   420.04 (+1.38%)
BAC   28.18 (+5.23%)
BA   204.81 (+11.13%)
MSFT   187.46 (+2.48%)
FB   230.86 (+2.02%)
GOOGL   1,442.15 (+1.97%)
AMZN   2,487.30 (+1.09%)
NVDA   358.50 (+2.24%)
CGC   16.53 (-0.60%)
BABA   219.69 (+0.76%)
MU   54.01 (+5.45%)
GE   7.91 (+2.20%)
TSLA   885.50 (+2.44%)
T   32.82 (+3.21%)
ACB   13.90 (-2.32%)
F   7.32 (+11.42%)
GILD   76.90 (-0.83%)
DIS   124.79 (+0.89%)
NFLX   420.04 (+1.38%)
BAC   28.18 (+5.23%)
BA   204.81 (+11.13%)
MSFT   187.46 (+2.48%)
FB   230.86 (+2.02%)
GOOGL   1,442.15 (+1.97%)
AMZN   2,487.30 (+1.09%)
NVDA   358.50 (+2.24%)
CGC   16.53 (-0.60%)
BABA   219.69 (+0.76%)
MU   54.01 (+5.45%)
GE   7.91 (+2.20%)
TSLA   885.50 (+2.44%)
T   32.82 (+3.21%)
ACB   13.90 (-2.32%)
F   7.32 (+11.42%)
GILD   76.90 (-0.83%)
DIS   124.79 (+0.89%)
NFLX   420.04 (+1.38%)
BAC   28.18 (+5.23%)
BA   204.81 (+11.13%)
Log in

NASDAQ:NURONeurometrix Stock Price, Forecast & News

$2.00
+0.03 (+1.52 %)
(As of 06/5/2020 03:28 PM ET)
Add
Compare
Today's Range
$1.93
Now: $2.00
$2.04
50-Day Range
$2.04
MA: $2.46
$3.65
52-Week Range
$0.81
Now: $2.00
$7.00
Volume8,924 shs
Average Volume445,924 shs
Market Capitalization$4.14 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.
Read More
Neurometrix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NURO
CUSIPN/A
Phone781-890-9989

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.27 million
Book Value$1.81 per share

Profitability

Net Income$-3,770,000.00

Miscellaneous

Employees42
Market Cap$4.14 million
Next Earnings Date7/16/2020 (Estimated)
OptionableNot Optionable

Receive NURO News and Ratings via Email

Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.

Neurometrix (NASDAQ:NURO) Frequently Asked Questions

How has Neurometrix's stock been impacted by COVID-19 (Coronavirus)?

Neurometrix's stock was trading at $1.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NURO shares have increased by 41.8% and is now trading at $2.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neurometrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neurometrix.

When is Neurometrix's next earnings date?

Neurometrix is scheduled to release its next quarterly earnings announcement on Thursday, July 16th 2020. View our earnings forecast for Neurometrix.

How were Neurometrix's earnings last quarter?

Neurometrix Inc (NASDAQ:NURO) announced its quarterly earnings data on Thursday, April, 23rd. The medical device company reported ($0.45) earnings per share (EPS) for the quarter. The medical device company earned $2.17 million during the quarter. Neurometrix had a negative return on equity of 138.44% and a negative net margin of 77.88%. View Neurometrix's earnings history.

When did Neurometrix's stock split? How did Neurometrix's stock split work?

Neurometrix shares reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for NURO?

1 brokers have issued 1 year target prices for Neurometrix's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Neurometrix's stock price to reach $5.00 in the next year. This suggests a possible upside of 150.0% from the stock's current price. View analysts' price targets for Neurometrix.

Has Neurometrix been receiving favorable news coverage?

Media headlines about NURO stock have trended positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neurometrix earned a news sentiment score of 2.4 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutNeurometrix.

Are investors shorting Neurometrix?

Neurometrix saw a increase in short interest in May. As of May 15th, there was short interest totaling 86,200 shares, an increase of 66.1% from the April 30th total of 51,900 shares. Based on an average daily trading volume, of 997,200 shares, the days-to-cover ratio is currently 0.1 days. Approximately 3.2% of the shares of the company are short sold. View Neurometrix's Current Options Chain.

Who are some of Neurometrix's key competitors?

What other stocks do shareholders of Neurometrix own?

Who are Neurometrix's key executives?

Neurometrix's management team includes the following people:
  • Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 54)
  • Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 67)
  • Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 58)
  • Mr. Michael J. MacDonald, Sr. VP of Commercial Operations & GM of Diagnostics
  • Dr. Xuan Kong Ph.D., Chief Data Scientist

What is Neurometrix's stock symbol?

Neurometrix trades on the NASDAQ under the ticker symbol "NURO."

Who are Neurometrix's major shareholders?

Neurometrix's stock is owned by a number of institutional and retail investors. Top institutional investors include Sabby Management LLC (3.97%). View institutional ownership trends for Neurometrix.

Which major investors are buying Neurometrix stock?

NURO stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. View insider buying and selling activity for Neurometrix.

How do I buy shares of Neurometrix?

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurometrix's stock price today?

One share of NURO stock can currently be purchased for approximately $2.00.

How big of a company is Neurometrix?

Neurometrix has a market capitalization of $4.14 million and generates $9.27 million in revenue each year. The medical device company earns $-3,770,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. Neurometrix employs 42 workers across the globe.

What is Neurometrix's official website?

The official website for Neurometrix is www.neurometrix.com.

How can I contact Neurometrix?

Neurometrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.